Market Place
Sourcing Support
Corbus Pharma Q3 2024 Results & Corporate Update
07 Nov 2024 //
GLOBENEWSWIRE
Corbus Pharma Presents CRB-913 Data at ObesityWeek® 2024
04 Nov 2024 //
GLOBENEWSWIRE
Corbus Pharma to Present at Healthcare Innovation Conference
29 Oct 2024 //
GLOBENEWSWIRE
Corbus Completes Enrollment Of CRB-701 Phase 1 Trial
16 Oct 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals To Participate In BMO Oncology Summit
26 Sep 2024 //
GLOBENEWSWIRE
Corbus To Present At Cantor Global Health Conference
05 Sep 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Appoints Winston Kung To Board Of Directors
20 Aug 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Reports Q2 2024 Results And Corporate Update
06 Aug 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
30 Jul 2024 //
GLOBENEWSWIRE
SYS6002 Nectin-4 ADC Shows Safety, Efficacy In Positive Tumor Patients
01 Jun 2024 //
GLOBENEWSWIRE
Corbus At Goldman Sachs Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Corbus Pharma At RBC Healthcare Conference 2024
09 May 2024 //
GLOBENEWSWIRE
Corbus Reports Q1 2024 Financials And Corporate Update
07 May 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
01 May 2024 //
GLOBENEWSWIRE
Corbus Abstract Accepted for ASCO 2024 Presentation
24 Apr 2024 //
GLOBENEWSWIRE
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial
02 Apr 2024 //
GLOBENEWSWIRE
Corbus Reports Fourth Quarter and Year-End 2023 Financial Results
12 Mar 2024 //
GLOBENEWSWIRE
Corbus to Participate in the BMO Capital Markets Inaugural Obesity Summit
06 Mar 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
28 Feb 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Conference
06 Feb 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Announces Pricing of Public Offering
31 Jan 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Announces Proposed Public Offering
30 Jan 2024 //
GLOBENEWSWIRE
CRB-701 Demonstrates Efficacy in Patients with Nectin-4 Positive Tumors
26 Jan 2024 //
GLOBENEWSWIRE
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
23 Jan 2024 //
GLOBENEWSWIRE
Corbus Pharma Announces Abstract Accepted for Presentation at 2024 ASCO GU
18 Dec 2023 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on CRB-601
02 Nov 2023 //
GLOBENEWSWIRE
Corbus Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor
17 Oct 2023 //
GLOBENEWSWIRE
Corbus Presents the Characterization of its Next Generation Nectin-4 ADC CRB-701
16 Oct 2023 //
GLOBENEWSWIRE
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its CRB-601
27 Sep 2023 //
PR NEWSWIRE
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701
19 Sep 2023 //
PR NEWSWIRE
Corbus Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
PR NEWSWIRE
Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
31 Jul 2023 //
PR NEWSWIRE
Corbus Pharmaceuticals Set to Join Russell Microcap® Index
26 Jun 2023 //
PR NEWSWIRE
Corbus Pharmaceuticals to Participate in 2023 Jefferies Healthcare Conference
31 May 2023 //
PR NEWSWIRE
Corbus Pharmaceuticals Reports1Q 2023 FYR and Provides Corporate Update
09 May 2023 //
PR NEWSWIRE
Corbus to Present Latest Pre-Clinical Data on CRB-601 av?8 Blocking Antibody
01 May 2023 //
PR NEWSWIRE
Corbus Hosting Virtual `Meet the Expert` Series: Blocking TGF? with CRB-601
18 Apr 2023 //
PR NEWSWIRE
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601
17 Apr 2023 //
PR NEWSWIRE
Corbus Pharma Data on CRB-601 av?8 Blocking Antibody Accepted for Presentation
14 Mar 2023 //
PR NEWSWIRE
Corbus Pharma Reports Fourth Quarter 2022 and Year-End Financial Results
07 Mar 2023 //
PR NEWSWIRE
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben
06 Mar 2023 //
PR NEWSWIRE
Corbus to Present at the Oppenheimer 33rd Annual Healthcare Conference
02 Mar 2023 //
PR NEWSWIRE
Corbus expands oncology pipeline with the addition of Nectin-4 targeting ADC
13 Feb 2023 //
PR NEWSWIRE
Tiny Corbus pays $7.5M for rival to Seagen`s oncology ADC Padcev
13 Feb 2023 //
FIERCE BIOTECH
Corbus Presents Latest Preclinical Data for CRB-601 at SITC
10 Feb 2023 //
PRESS RELEASE
Corbus Presents Latest Preclinical Data for CRB-601 at the Society for (SITC)
10 Nov 2022 //
PRNEWSWIRE
Corbus Reports3Q 2022 Financial Results and Provides Corporate Update
08 Nov 2022 //
PRNEWSWIRE
Corbus to Present Pre-Clinical Data for CRB-601 at the SITC 37th Annual Meeting
14 Oct 2022 //
PRNEWSWIRE
Corbus Pharma Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
PRNEWSWIRE
Corbus Presents Latest Preclinical Data for CRB-601
11 May 2022 //
PRNEWSWIRE
Corbus Presents First Preclinical Data for CRB-601 at the AACR
08 Apr 2022 //
PRNEWSWIRE
Corbus Pharma Reports Q4 and Year-End 2021 Financial Results
08 Mar 2022 //
PRNEWSWIRE
Corbus snags Takeda`s cancer leader to boost early-stage assets
08 Dec 2021 //
FIERCEBIOTECH
Corbus notches another trial setback in a long line of failures
25 Jun 2021 //
FIERCEBIOTECH
Corbus Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study
20 Apr 2021 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE
30 Mar 2021 //
GLOBENEWSWIRE
Corbus Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
09 Nov 2020 //
GLOBENEWSWIRE
Corbus Announces Presentation of Data from its Ph 2b Study in Cystic Fibrosis
23 Oct 2020 //
PRESS RELEASE
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented
21 Oct 2020 //
PRESS RELEASE
